OXFORD, England, October 1, 2013 /PRNewswire/ --
OBN's Annual Awards Dinner this evening celebrated the achievements and major success stories in biotech, medtech and diagnostics over the past year at a black tie event at The Ashmolean Museum, Oxford. The Awards seek to highlight the many achievements of the UK's bioscience sector in raising funds, executing deals and supporting innovation. OBN's Awards recognize these achievements, taking into account its significance for the stage of development of a nominated life sciences company, as well as the scale of the achievement.
The 2013 award winners were:
Circassia, Best New Biotech Development Programme
Award Presented by J A Kemp
Circassia's ToleroMune® cat allergy treatment maintained symptom improvement two years after the start of Short-Course Therapy in a phase II clinical trial, while their HDM-SPIRE treatment for house dust mite allergy also achieved long-term symptom reduction.
OrganOx, Best New Medtech Development Programme
Award Presented by Citigate
OrganOx has developed metra™ - a system which enables the repair, preservation and objective viability assessment of livers prior to transplantation. It has already been used successfully for several transplantation procedures in 2013.
Autifony Therapeutics, Best Emerging Biotech
Award Presented by James Cowper
Autifony is developing new drugs to treat hearing disorders by targeting specific ion channels which regulate neuronal activity within the auditory system. A top up series A round of £5.5m in June 2013 brings funds raised to £15.5m, plus a £2
Copyright©2012 PR Newswire.
All rights reserved